Enabling innovation by connecting an ecosystem of partnersCOVID-19 has been a shock to the system for every industry, not least pharma, but the sector is Share XEnabling innovation by connecting an ecosystem of partnershttps://pharmaphorum.com/r-d/enabling-innovation-by-connecting-an-ecosystem-of-partners/
NICE talking to you: Trends in early HTA engagementWith exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Share XNICE talking to you: Trends in early HTA engagementhttps://pharmaphorum.com/views-analysis-market-access/nice-talking-to-you/
Pharma’s response to COVID: GSKA few months into the pandemic, the world is now moving beyond managing the crisis, with more focus Share XPharma’s response to COVID: GSKhttps://pharmaphorum.com/views-analysis-sales-marketing/pharmas-response-to-covid-gsk/
Why intelligent automation is the future for regulatoryThere are a host of new, previously unimaginable tools and techniques – from analytics to robotic process automation Share XWhy intelligent automation is the future for regulatoryhttps://pharmaphorum.com/views-analysis-digital/why-intelligent-automation-is-the-future-for-regulatory/
Life science leaders sign new ‘Biotech Social Pact’ for EuropeThe signatories of a new Biotech Social Pact with Europe and patients explain why healthcare calls for a Share XLife science leaders sign new ‘Biotech Social Pact’ for Europehttps://pharmaphorum.com/views-analysis-market-access/life-science-leaders-sign-new-biotech-social-pact-for-europe/
A history of AstraZenecaA look back at AstraZeneca and its roots in the UK and Sweden Share XA history of AstraZenecahttps://pharmaphorum.com/views-analysis-sales-marketing/a_history_of-_astrazeneca/
Transformational value – preparing for a decade of radical changeThe pharmaceutical industry is at an inflection point, where ground-breaking innovation must be translated into transformational value for Share XTransformational value – preparing for a decade of radical changehttps://pharmaphorum.com/whitepapers/preparing-for-a-decade-of-radical-change-in-pharma-transformational-value/
Unpleasant truth: the pandemic, record debt and our opportunity for sustainabilitySandoz’s Pierre Bourdage looks at the unexpected secondary impacts of COVID-19 on countries and healthcare systems, and asks Share XUnpleasant truth: the pandemic, record debt and our opportunity for sustainabilityhttps://pharmaphorum.com/views-analysis-digital/unpleasant-truth-pandemic-record-debt-sustainability/
Rises in non-submissions to NICE: do they matter?Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off Share XRises in non-submissions to NICE: do they matter?https://pharmaphorum.com/views-analysis-market-access/rises-in-non-submissions-to-nice-do-they-matter/
